| |
| |
| |
 |
| |
Arndt F. Schilling, Sandra Filke, Silja Brink, Heike Korbmacher, Michael Amling
Johannes M. Rueger
|
| |
|
| |
|
 |
| |
There is a growing market of biomaterials for orthopedic
applications. As soon as these materials are surgically
introduced into the constantly remodeling bone
of the patient, they start to interact with the local cells:
osteoblasts and osteoclasts. At the first glance, the bone
building osteoblasts seem to be the more important
cells for osseointegration of implants. However, it is
mainly the bone resorbing action of osteclasts that determines
the longevity of the implant. In this paper, we
give a short overview over the current understanding of
osteoclast biology; we review the interaction between
biomaterials, biomaterial particles and osteoclasts, and
the effects of treatment with antiosteoclastic agents
like bisphosphonates on biomaterial implant healing. |
| |
|
| |
|
|
|
